Fig. 1From: China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapyStudy design of the ALTER0303 trial. NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptorBack to article page